Symbols / XBI
XBI Chart
About
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Fundamentals
Scroll to Statements| Sector | — | Industry | — | Market Cap | — |
| Enterprise Value | — | Income | — | Sales | — |
| Book/sh | — | Cash/sh | — | Dividend Yield | 36.00% |
| Payout | — | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | — | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | — | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | — |
| ROE | — | ROIC | — | Gross Margin | — |
| Oper. Margin | — | Profit Margin | — | Shs Outstand | — |
| Shs Float | — | Short Float | — | Short Ratio | — |
| Short Interest | — | 52W High | 132.09 | 52W Low | 66.66 |
| Beta | — | Avg Volume | 9.26M | Volume | 9.42M |
| Target Price | — | Recom | — | Prev Close | $126.97 |
| Price | $129.16 | Change | 1.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
—
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
No analyst ratings or price targets available.
News
RSS: Latest XBI news- Discipline and Rules-Based Execution in XBI Response - Stock Traders Daily Sun, 22 Feb 2026 02
- Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)? - Nasdaq hu, 19 Feb 2026 11
- A Golden Age of Biotech Is Upon Us, Thanks to AI. This ETF Offers 40% Upside. - Barron's Wed, 18 Feb 2026 01
- Should You Invest in the SPDR S&P Biotech ETF (XBI)? - Yahoo Finance Mon, 13 Oct 2025 07
- Biotech: Time For A Pause To Start 2026 - Seeking Alpha Fri, 02 Jan 2026 08
- Biotech ETF (XBI) Hits New 52-Week High - Zacks Investment Research Mon, 17 Nov 2025 08
- Why biotech stocks did unusually well yesterday - statnews.com Wed, 03 Sep 2025 07
- Have Biotech Stocks Returned To Health After Years Of Sickness? - Investor's Business Daily Fri, 24 Oct 2025 07
- Final Trades: Taiwan Semi, Apple and the XBI - CNBC Mon, 24 Nov 2025 08
- SPDR S&P Biotech ETF (XBI) Top 25 Holdings - TIKR.com Wed, 24 Sep 2025 07
- Biotech and Pharma Stocks Tumble as Investors Race into Energy - Barron's Mon, 05 Jan 2026 08
- Behavioral Patterns of XBI and Institutional Flows - Stock Traders Daily Wed, 11 Feb 2026 08
- Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - Yahoo Finance hu, 10 Jul 2025 07
- Biotech Stocks Are Up. The Sector Is Looking Better Than It Has in Years. - Barron's Mon, 06 Oct 2025 07
- Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? - Yahoo Finance ue, 16 Sep 2025 07
Insider Transactions
No recent insider transactions.
Financials
No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for XBI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|